Beat Fierz/EPFL

Single-Molecule Dissection Of Developmental Gene Control

ArticlePress release
Current Medical News
Contributed byKrish Tangella MD, MBAOct 25, 2017

Scientists at EPFL and Max Plank have made significant discoveries on how developmental genes are controlled by the methyltransferase enzyme PRC2. The study is published in Nature Structural & Molecular Biology.

Polycomb repressive complex 2 (PRC2) is part of a larger system of proteins that work together to repress the expression of developmental genes. PRC2 does this by adding up to three methyl groups to a specific lysine amino acid (lysine 27) of the histone H3 protein. Trimethylation (three methyl groups) of lysine 27 in particular is important, as turns off the expression of specific genes during development.

Such gene repression requires a high concentration of lysine 27 trimethylation within defined chromatin (DNA wrapped around histones) regions, since mutations that prevent this process result in developmental defects or cancer. For maximum activity, PRC2 needs further "accessory factors," which vary between species. In humans, a main accessory factor is PHF1.

Now, the labs of Beat Fierz at EPFL and Jürg Muller at the MPI combined chemical biology, biophysics, and structural studies to identify the mechanism by which PHF1 increases the activity of the PRC2 enzyme.

The scientists used single-molecule fluorescence imaging to directly observe human PHF1-PRC2 complexes interacting with synthetic chromatin fibers in real-time. These experiments revealed that PHF1 proteins anchor PRC2 on chromatin, increasing their local activity.

Structural analysis showed that PHF1 contains a previously unknown DNA-binding domain whose interactions with the nucleosomal DNA is critical for anchoring PRC2 to chromatin and for increasing its activity. Essentially, this DNA-binding domain is the key to efficient gene regulation across different species. As the authors write: "…a major part of the binding affinity of PRC2 for nucleosomes comes from interactions of the complex with DNA."

The authors draw three conclusions from the findings: First, that the binding affinity of PRC2 for chromatin substrate is determined by its interactions with DNA. Second, that increased anchoring of PRC2 to chromatin via PHF1 depends on a newly identified structural unit in PHF1. And third, that stable PRC2 chromatin interactions, mediated by PHF1, are key for increased lysine trimethylation in chromatin -- and thus for gene repression.

"We are excited by the ability to combine chemistry and imaging to observe fundamental molecular processes on the single-molecule scale and in real-time," says Beat Fierz. "These approaches really provide new avenues to understand biology with chemical precision, as demonstrated here for PRC2-dependent gene regulation."


Materials provided by Ecole Polytechnique Federale de Lausanne (EPFL)Note: Content may be edited for style and length.

Disclaimer: DoveMed is not responsible for the accuracy of the adapted version of news releases posted to DoveMed by contributing universities and institutions.

References:

Jeongyoon Choi, Andreas Linus Bachmann, Katharina Tauscher, Christian Benda, Beat Fierz, Jürg Müller. (2017). DNA binding by PHF1 prolongs PRC2 residence time on chromatin and thereby promotes H3K27 methylationNature Structural & Molecular Biology. DOI: 10.1038/nsmb.3488

Was this article helpful

On the Article

Krish Tangella MD, MBA picture
Approved by

Krish Tangella MD, MBA

Pathology, Medical Editorial Board, DoveMed Team

0 Comments

Please log in to post a comment.

Related Articles

Test Your Knowledge

Asked by users

Related Centers

Loading

Related Specialties

Loading card

Related Physicians

Related Procedures

Related Resources

Join DoveHubs

and connect with fellow professionals

Related Directories

Who we are

At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.

© 2023 DoveMed. All rights reserved. It is not the intention of DoveMed to provide specific medical advice. DoveMed urges its users to consult a qualified healthcare professional for diagnosis and answers to their personal medical questions. Always call 911 (or your local emergency number) if you have a medical emergency!